New drug combo shows early potential for treating pancreatic cancer

The new therapy, which is a combination of three drugs that help boost the body's immune defences against tumors, is likely to enter clinical trials later this year

Representative image
Representative image
user

IANS

In a bid to help doctors treat pancreatic cancer in a better way, a team of MIT researchers has developed an immunotherapy strategy.

The study, published in the journalACancer Cell, indicates that the immunotherapy strategy has shown that it can eliminate pancreatic tumors in mice.

The new therapy, which is a combination of three drugs that help boost the body's immune defences against tumors, is likely to enter clinical trials later this year.

"We don't have a lot of good options for treating pancreatic cancer. It's a devastating disease clinically," said researcher William Freed-Pastor from the Massachusetts Institute of Technology in the US.

According to the researchers, pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.

The researchers said that the body's immune system contains T cells that can recognise and destroy cells that express cancerous proteins, but most tumors create a highly immunosuppressive environment that disables these T cells, helping the tumour to survive.

Immune checkpoint therapy -- the most common form of immunotherapy currently being used clinically -- works by removing the brakes on these T cells, rejuvenating them so they can destroy tumours.


One class of immunotherapy drug that has shown success in treating many types of cancer targets the interactions between PD-L1, a cancer-linked protein that turns off T cells, and PD-1, the T cell protein that PD-L1 binds to.

Drugs that block PD-L1 or PD-1, also called checkpoint inhibitors, have been approved to treat cancers such as melanoma and lung cancer, but they have very little effect on pancreatic tumours.

Alongside the clinical trial, the MIT team plans to analyse which types of pancreatic tumours might respond best to this drug combination.

Click here to join our official telegram channel (@nationalherald) and stay updated with the latest headlines